loading...

09 October 2020 04:35

Stephen Curry Golden State Warriors New Orleans Pelicans

Sareum to get US patent on SDC-1802 programme

Shares of Sareum Holdings Plc (LON: SAR) today surged 16% after the biotech company announced that it was close to winning US patent protection for its cancer immunotherapy programme. The company expects the US Patent and Trademark Office to issue the patent within the next three months after issuing a notice of allowance offering protection for the SDC-1802 molecule, a pre-clinical cancer immunotherapy drug candidate. Dr John Reader, Sareum's chief scientific officer, said: "The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 programme across all major markets." Subject to certain formalities, the company expects the patent will be granted within the next three months () said the US Patent and Trademark Office has issued what is called a notice of allowance offering protection for its pre-clinical cancer immunotherapy drug candidate. The patent will protect the SDC-1802 molecule and its pharmaceutical preparation. In statement, Dr John Reader, Sareum's chief scientific officer, said: "The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 programme across all major markets.

Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent on an invention associated with its proprietary 'SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme'. The AIM-traded firm said the programme was in preclinical development, targeting cancer and cancer immunotherapy. It said the patent, application number 16/351,620, would protect the SDC-1802 molecule and pharmaceutical preparations of it. Subject to certain formalities being completed, the company said it expected that the patent would be granted within three months. The board said it followed similar patent protection granted in Europe, as announced on 10 November 2014, and in Japan and China, as announced on 19 December 2017.

"The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 programme across all major markets," said chief scientific officer Dr John Reader. "The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company's negotiating position as it continues to engage in discussions with potential licence partners." Cambridge drug development business Sareum Holdings plc saw its share price rise more than 13 per cent in the UK after receiving a patent boost in the US. The AIM-quoted company is delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. In a genuine breakthrough development, Sareum reveals that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme. The patent will protect the SDC-1802 molecule and pharmaceutical preparations arising from the research.

Subject to certain formalities being completed, the company expects that the patent will be granted within three months.T his will complete the patent protection for this programme across all major territories. The landmark follows similar patent protection being granted to the company in Europe, Japan and China. Sareum's CSO Dr John Reader said: "The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets. "The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company's negotiating position as it continues to engage in discussions with potential licence partners." US Patent Allowance for Sareum's SDC-1802 TYK2/JAK1 Inhibitor Cambridge, UK, 8 October 2020 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the 'SDC-1802 Programme'). This programme is in preclinical development and targets cancer and cancer immunotherapy.

16/351,620) will protect the SDC-1802 molecule and pharmaceutical preparations thereof. Subject to certain formalities being completed, the Company expects that the patent will be granted within three months. Following the grant of this patent, Sareum will have approved patent protection in the US for its SDC-1802 Programme and the grant will complete the patent protection for this programme across all major territories. This follows similar patent protection being granted to the Company in Europe, announced on 10 November 2014, and in Japan and China, announced on 19 December 2017. 'The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets.

The Board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the Company's negotiating position as it continues to engage in discussions with potential licence partners.' Strand Hanson Limited (Nominated Adviser) Hybridan LLP (Nominated Broker) Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company. Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.